Celularity Statistics
Total Valuation
Celularity has a market cap or net worth of $50.62 million. The enterprise value is $118.33 million.
| Market Cap | 50.62M |
| Enterprise Value | 118.33M |
Important Dates
The last earnings date was Tuesday, September 29, 2026, after market close.
| Earnings Date | Sep 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Celularity has 32.45 million shares outstanding. The number of shares has increased by 20.39% in one year.
| Current Share Class | 32.45M |
| Shares Outstanding | 32.45M |
| Shares Change (YoY) | +20.39% |
| Shares Change (QoQ) | +6.49% |
| Owned by Insiders (%) | 10.92% |
| Owned by Institutions (%) | 11.80% |
| Float | 22.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.67 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.09
| Current Ratio | 0.09 |
| Quick Ratio | 0.07 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.65 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -32.32% |
| Return on Invested Capital (ROIC) | -211.75% |
| Return on Capital Employed (ROCE) | -204.33% |
| Weighted Average Cost of Capital (WACC) | 6.74% |
| Revenue Per Employee | $164,957 |
| Profits Per Employee | -$620,061 |
| Employee Count | 115 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 5.39 |
Taxes
In the past 12 months, Celularity has paid $3,000 in taxes.
| Income Tax | 3,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.44% in the last 52 weeks. The beta is 0.78, so Celularity's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | -27.44% |
| 50-Day Moving Average | 1.20 |
| 200-Day Moving Average | 1.10 |
| Relative Strength Index (RSI) | 57.76 |
| Average Volume (20 Days) | 160,341 |
Short Selling Information
The latest short interest is 821,020, so 2.53% of the outstanding shares have been sold short.
| Short Interest | 821,020 |
| Short Previous Month | 1.90M |
| Short % of Shares Out | 2.53% |
| Short % of Float | 3.67% |
| Short Ratio (days to cover) | 0.07 |
Income Statement
In the last 12 months, Celularity had revenue of $18.97 million and -$71.31 million in losses. Loss per share was -$2.65.
| Revenue | 18.97M |
| Gross Profit | 998,000 |
| Operating Income | -59.04M |
| Pretax Income | -71.09M |
| Net Income | -71.31M |
| EBITDA | -53.90M |
| EBIT | -59.04M |
| Loss Per Share | -$2.65 |
Balance Sheet
The company has $368,000 in cash and $68.08 million in debt, with a net cash position of -$67.71 million or -$2.09 per share.
| Cash & Cash Equivalents | 368,000 |
| Total Debt | 68.08M |
| Net Cash | -67.71M |
| Net Cash Per Share | -$2.09 |
| Equity (Book Value) | -35.26M |
| Book Value Per Share | -1.21 |
| Working Capital | -64.28M |
Cash Flow
| Operating Cash Flow | -8.81M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 5.15M |
| Net Borrowing | 3.79M |
| Free Cash Flow | -8.81M |
| FCF Per Share | -$0.27 |
Margins
| Gross Margin | 5.26% |
| Operating Margin | -311.25% |
| Pretax Margin | -374.72% |
| Profit Margin | n/a |
| EBITDA Margin | -284.12% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Celularity does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -20.39% |
| Shareholder Yield | -20.39% |
| Earnings Yield | -140.86% |
| FCF Yield | -17.41% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 157.40% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 29, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Feb 29, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Celularity has an Altman Z-Score of -16.26 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -16.26 |
| Piotroski F-Score | 2 |